PF-07934040 + pembrolizumab

PF-07934040 + pembrolizumab is a combination therapy under investigation for the treatment of advanced solid tumors harboring mutations in the KRAS gene. **PF-07934040** is an orally administered small molecule inhibitor that targets mutant KRAS, aiming to induce apoptosis and inhibit proliferation in tumor cells carrying these mutations. **Pembrolizumab** is a monoclonal antibody immune checkpoint inhibitor that blocks PD-1, enhancing T-cell mediated anti-tumor activity. The combination is in phase 1 clinical trials for cancers such as pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer with KRAS mutations. PF-07934040 is developed by Pfizer, and pembrolizumab by Merck.

Other names

PembroLambrolizumab